The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedx Pharma Regulatory News (REDX)

Share Price Information for Redx Pharma (REDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 30.00
Bid: 27.00
Ask: 33.00
Change: 18.60 (163.16%)
Spread: 6.00 (22.222%)
Open: 12.00
High: 30.00
Low: 11.50
Prev. Close: 11.40
REDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) Redx Pharma plc

17 Mar 2020 14:30

RNS Number : 4869G
Redx Pharma plc
17 March 2020
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Redx Pharma plc ("Redx")

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Redx Pharma plc

(d) Is the discloser the offeror or the offeree?

OFFEROR / OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

17 March 2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

YES / NO / N/A

If YES, specify which:

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

1p ordinary shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

n/a

n/a

(2) Cash-settled derivatives:

 

n/a

n/a

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

n/a

n/a

 

TOTAL:

n/a

n/a

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

n/a

Details, including nature of the rights concerned and relevant percentages:

n/a

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

Interest of Redx Directors and connected advisers in Redx shares:

Name

Number of Shares

% of issued share capital

Iain Ross

600,000

0.32

Dr. Bernhard Kirschbaum

50,000

0.02

Peter Presland

120,000

0.06

WG Partners LLP

114,593

0.06

 

Interest of Redx Directors in options over Redx shares:

Name

No. of options

Exercise price

Vesting date

Expiry date

Lisa Anson

600,000

13.75p

4 June 2018

3 June 2028

Lisa Anson

600,000

20p

4 June 2018

3 June 2028

Lisa Anson

600,000

27p

4 June 2019

3 June 2028

Lisa Anson

600,000

35p

4 June 2019

3 June 2028

Lisa Anson

600,000

42.5p

4 June 2020

3 June 2028

Lisa Anson

600,000

50p

4 June 2020

3 June 2028

Dr. James Mead

200,000

13.75p

13 February 2019

12 February 2029

Dr. James Mead

200,000

20p

13 February 2019

12 February 2029

Dr. James Mead

200,000

27p

13 February 2020

12 February 2029

Dr. James Mead

200,000

35p

13 February 2020

12 February 2029

Dr. James Mead

200,000

42.5p

13 February 2021

12 February 2029

Dr. James Mead

200,000

50p

13 February 2021

12 February 2029

 

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

YES/NO

Supplemental Form 8 (SBL)

YES/NO

 

 

Date of disclosure:

17 March 2020

Contact name:

James Mead

Telephone number:

01625 496 609

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEEFLFLSVSIDLII
Date   Source Headline
2nd Jul 20202:05 pmRNSSecond Price Monitoring Extn
2nd Jul 20202:00 pmRNSPrice Monitoring Extension
1st Jul 202012:30 pmRNSDirector/PDMR Shareholding
30th Jun 202011:30 amRNSHolding(s) in Company
30th Jun 20207:46 amRNSShare Option Scheme
30th Jun 20207:02 amRNSInterim Results
30th Jun 20207:00 amRNSProposed financing of $30m and notice of GM
15th Jun 202011:05 amRNSSecond Price Monitoring Extn
15th Jun 202011:00 amRNSPrice Monitoring Extension
20th May 20207:00 amRNSChange of Adviser
18th May 20207:00 amRNSAppointment of Non-Executive Director
6th May 20208:45 amRNSHolding(s) in Company
5th May 20209:45 amRNSHolding(s) in Company
4th May 20209:32 amRNSForm 8.3 - [REDX PHARMA PLC]
1st May 202011:45 amRNSForm 8.5 (EPT/RI)
1st May 20207:00 amRNSOffer Closed
29th Apr 202011:45 amRNSForm 8.5 (EPT/RI)
23rd Apr 202011:45 amRNSForm 8.5 (EPT/RI)
23rd Apr 202011:32 amRNSResult of AGM and operational update
21st Apr 202011:45 amRNSForm 8.5 (EPT/RI)
20th Apr 202011:45 amRNSForm 8.5 (EPT/RI)
17th Apr 202011:45 amRNSForm 8.5 (EPT/RI)
15th Apr 202011:45 amRNSForm 8.5 (EPT/RI)
14th Apr 202011:45 amRNSForm 8.5 (EPT/RI)
9th Apr 20206:10 pmRNSRedx Pharma
9th Apr 20204:47 pmRNSPUBLICATION OF OFFER DOCUMENT
9th Apr 20201:58 pmRNSOffer Update - Share Acquisitions
7th Apr 202011:45 amRNSForm 8.5 (EPT/RI)
6th Apr 202011:45 amRNSForm 8.5 (EPT/RI)
3rd Apr 20209:44 amRNSForm 8 (DD) - Redx Pharma PLC
3rd Apr 20209:27 amRNSForm 8.5 - RedX Pharma Plc
3rd Apr 20209:14 amRNSHolding(s) in Company
3rd Apr 20207:00 amRNSForm 8.3 - Redx Pharma plc
2nd Apr 20202:31 pmRNSOffer Update - Share Acquisitions
2nd Apr 202012:27 pmRNSForm 8.5 - RedX Pharma Plc
2nd Apr 202011:45 amRNSForm 8.5 (EPT/RI)
2nd Apr 202011:20 amRNSHolding(s) in Company
2nd Apr 20209:55 amRNSForm 8 (DD) - Redx Pharma PLC
1st Apr 202012:13 pmRNSForm 8.5 - Redx Pharma Plc
1st Apr 202011:01 amRNSForm 8 (DD) - Redx Pharma PLC
31st Mar 20207:00 amRNSInformation regarding Company AGM
30th Mar 202011:45 amRNSForm 8.5 (EPT/RI)
30th Mar 20207:00 amRNS£5 million short term loan agreement
27th Mar 202011:45 amRNSForm 8.5 (EPT/RI)
27th Mar 202011:43 amRNSForm 8 (OPD) - Redx Pharma Plc
26th Mar 20202:03 pmRNSForm 8.3 - Redx Pharma plc
26th Mar 20201:42 pmRNSForm 8.3 - Redx Pharma plc
26th Mar 202011:45 amRNSForm 8.5 (EPT/RI)
25th Mar 202011:45 amRNSHolding(s) in Company
25th Mar 202011:45 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.